XML 84 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by the CODM are reported on the condensed consolidated statements of earnings for the periods ended September 30, 2025 and 2024. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
The following table details AbbVie’s worldwide net revenues:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2025202420252024
Immunology
SkyriziUnited States$4,085 $2,778 $10,847 $6,774 
International623 427 1,709 1,166 
Total$4,708 $3,205 $12,556 $7,940 
RinvoqUnited States$1,559 $1,170 $4,231 $2,912 
International625 444 1,699 1,225 
Total$2,184 $1,614 $5,930 $4,137 
HumiraUnited States$619 $1,765 $2,165 $5,896 
International374 462 1,129 1,415 
Total$993 $2,227 $3,294 $7,311 
Neuroscience
VraylarUnited States$931 $873 $2,592 $2,338 
International3 2 7 5 
Total$934 $875 $2,599 $2,343 
Botox TherapeuticUnited States$825 $708 $2,323 $1,988 
International160 140 456 422 
Total$985 $848 $2,779 $2,410 
UbrelvyUnited States$344 $261 $907 $685 
International10 8 25 18 
Total$354 $269 $932 $703 
QuliptaUnited States$252 $168 $661 $442 
International36 8 87 15 
Total$288 $176 $748 $457 
VyalevUnited States$53 $— $81 $— 
International85 28 218 55 
Total$138 $28 $299 $55 
DuodopaUnited States$16 $24 $56 $72 
International80 87 233 267 
Total$96 $111 $289 $339 
Other NeuroscienceUnited States$42 $54 $148 $172 
International4 2 12 11 
Total$46 $56 $160 $183 
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2025202420252024
Oncology
ImbruvicaUnited States$507 $618 $1,579 $1,823 
Collaboration revenues199 210 619 676 
Total$706 $828 $2,198 $2,499 
VenclextaUnited States$341 $340 $974 $921 
International385 337 1,108 1,007 
Total$726 $677 $2,082 $1,928 
Elahere
United States
$150 $139 $453 $331 
International
20 — 55 — 
Total$170 $139 $508 $331 
Epkinly
Collaboration revenues
$44 $31 $129 $82 
International25 12 61 24 
Total$69 $43 $190 $106 
Other OncologyUnited States$11 $— $13 $— 
Aesthetics
Botox CosmeticUnited States$379 $414 $1,084 $1,253 
International258 257 801 780 
Total$637 $671 $1,885 $2,033 
Juvederm CollectionUnited States$98 $105 $278 $349 
International155 153 466 549 
Total$253 $258 $744 $898 
Other AestheticsUnited States$265 $272 $817 $828 
International38 38 128 119 
Total$303 $310 $945 $947 
Eye Care
OzurdexUnited States$32 $33 $92 $102 
International85 86 273 272 
Total$117 $119 $365 $374 
Lumigan/GanfortUnited States$42 $58 $142 $129 
International55 58 164 181 
Total$97 $116 $306 $310 
Alphagan/CombiganUnited States$9 $26 $35 $54 
International38 36 108 116 
Total$47 $62 $143 $170 
Other Eye CareUnited States$138 $123 $399 $421 
International110 105 316 321 
Total$248 $228 $715 $742 
Other Key Products
MavyretUnited States$146 $147 $472 $458 
International166 155 521 562 
Total$312 $302 $993 $1,020 
CreonUnited States$368 $338 $1,127 $995 
Linzess/ConstellaUnited States$315 $225 $701 $693 
International11 9 31 28 
Total$326 $234 $732 $721 
All other$660 $726 $2,010 $2,280 
Total net revenues$15,776 $14,460 $44,542 $41,232 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), intangible assets impairment expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7).